{"nodes": [{"id": "Eli Lilly", "investments": 21, "main_series": "Series A", "group": "Pharma"}, {"id": "Logos Capital", "investments": 14, "main_series": "Series A", "group": "Other life science"}, {"id": "Samsara BioCapital", "investments": 23, "main_series": "Series A", "group": "Other life science"}, {"id": "Johnson & Johnson Innovation", "investments": 34, "main_series": "Series A", "group": "Pharma"}, {"id": "Roche Venture Fund", "investments": 21, "main_series": "Series A", "group": "Pharma"}, {"id": "Matrix Partners", "investments": 9, "main_series": "Series A", "group": "Generalist"}, {"id": "DCVC", "investments": 28, "main_series": "Series A", "group": "Generalist"}, {"id": "Flagship Pioneering", "investments": 27, "main_series": "Series A", "group": "Tier A life science"}, {"id": "Venrock", "investments": 30, "main_series": "Series A", "group": "Tier A life science"}, {"id": "Morgenthaler Ventures", "investments": 12, "main_series": "Series A", "group": "Generalist"}, {"id": "Eight Roads Ventures", "investments": 12, "main_series": "Series A", "group": "Other life science"}, {"id": "Vida Ventures", "investments": 17, "main_series": "Series A", "group": "Other life science"}, {"id": "Sofinnova", "investments": 69, "main_series": "Series A", "group": "Tier A life science"}, {"id": "EcoR1 Capital", "investments": 14, "main_series": "Series A", "group": "Other life science"}, {"id": "Takeda", "investments": 29, "main_series": "Series A", "group": "Pharma"}, {"id": "Partners Innovation Fund", "investments": 20, "main_series": "Series A", "group": "Generalist"}, {"id": "Hatteras Venture Partners", "investments": 23, "main_series": "Series A", "group": "Other life science"}, {"id": "Nextech Invest", "investments": 12, "main_series": "Series A", "group": "Other life science"}, {"id": "Domain Associates", "investments": 39, "main_series": "Series A", "group": "Other life science"}, {"id": "Matrix Partners China", "investments": 7, "main_series": "Series A", "group": "Generalist"}, {"id": "Washington Research Foundation", "investments": 9, "main_series": "Series A", "group": "Other life science"}, {"id": "Catalio Capital Management", "investments": 10, "main_series": "Series A", "group": "Other life science"}, {"id": "New Science Ventures", "investments": 7, "main_series": "Series A", "group": "Other life science"}, {"id": "The Column Group", "investments": 28, "main_series": "Series A", "group": "Other life science"}, {"id": "Connecticut Innovations", "investments": 18, "main_series": "Series A", "group": "Generalist"}, {"id": "Lux Capital", "investments": 29, "main_series": "Series A", "group": "Generalist"}, {"id": "Pontifax", "investments": 11, "main_series": "Series A", "group": "Other life science"}, {"id": "5AM Ventures", "investments": 52, "main_series": "Series A", "group": "Tier A life science"}, {"id": "Canaan Partners", "investments": 37, "main_series": "Series A", "group": "Tier A life science"}, {"id": "Foresite Capital", "investments": 15, "main_series": "Series A", "group": "Other life science"}, {"id": "AME Cloud Ventures", "investments": 11, "main_series": "Series A", "group": "Generalist"}, {"id": "Altitude Life Science Ventures", "investments": 11, "main_series": "Series A", "group": "Other life science"}, {"id": "Surveyor Capital", "investments": 14, "main_series": "Series A", "group": "Generalist"}, {"id": "Janus Henderson", "investments": 14, "main_series": "Series A", "group": "Generalist"}, {"id": "Vertex Ventures", "investments": 11, "main_series": "Series A", "group": "Tier A life science"}, {"id": "ARCH Venture Partners", "investments": 103, "main_series": "Series A", "group": "Tier A life science"}, {"id": "Bayer", "investments": 18, "main_series": "Series A", "group": "Pharma"}, {"id": "Cormorant Asset Management", "investments": 21, "main_series": "Series A", "group": "Generalist"}, {"id": "Astellas Venture Management", "investments": 19, "main_series": "Series A", "group": "Pharma"}, {"id": "Atlas Venture", "investments": 69, "main_series": "Series A", "group": "Tier A life science"}, {"id": "F-Prime Capital", "investments": 56, "main_series": "Series A", "group": "Generalist"}, {"id": "HealthCare Ventures", "investments": 21, "main_series": "Series A", "group": "Other life science"}, {"id": "Novartis", "investments": 66, "main_series": "Series A", "group": "Pharma"}, {"id": "Polaris Ventures", "investments": 51, "main_series": "Series A", "group": "Tier A life science"}, {"id": "Novo Holding", "investments": 38, "main_series": "Series A", "group": "Tier A life science"}, {"id": "New Enterprise Associates", "investments": 65, "main_series": "Series A", "group": "Generalist"}, {"id": "RiverVest", "investments": 17, "main_series": "Series A", "group": "Other life science"}, {"id": "Lilly Asia Ventures", "investments": 22, "main_series": "Series A", "group": "Pharma"}, {"id": "Alexandria", "investments": 102, "main_series": "Series A", "group": "Tier A life science"}, {"id": "Amgen", "investments": 22, "main_series": "Series A", "group": "Pharma"}, {"id": "Fonds de solidarit FTQ", "investments": 7, "main_series": "Series A", "group": "Generalist"}, {"id": "OrbiMed", "investments": 91, "main_series": "Series A", "group": "Tier A life science"}, {"id": "Third Rock Ventures", "investments": 42, "main_series": "Series A", "group": "Tier A life science"}, {"id": "Vivo Capital", "investments": 35, "main_series": "Series A", "group": "Other life science"}, {"id": "OUP Osage University Partners", "investments": 39, "main_series": "Series A", "group": "Generalist"}, {"id": "Frazier Healthcare Partners", "investments": 37, "main_series": "Series A", "group": "Tier A life science"}, {"id": "Pfizer", "investments": 40, "main_series": "Series A", "group": "Pharma"}, {"id": "Leaps by Bayer", "investments": 14, "main_series": "Series A", "group": "Pharma"}, {"id": "Invus", "investments": 13, "main_series": "Series A", "group": "Generalist"}, {"id": "Lundbeck", "investments": 9, "main_series": "Series A", "group": "Other life science"}, {"id": "MPM Capital", "investments": 58, "main_series": "Series A", "group": "Tier A life science"}, {"id": "Obvious Ventures", "investments": 11, "main_series": "Series A", "group": "Generalist"}, {"id": "Casdin Capital", "investments": 33, "main_series": "Series A", "group": "Other life science"}, {"id": "Versant Ventures", "investments": 67, "main_series": "Series A", "group": "Tier A life science"}, {"id": "Elm Street Ventures", "investments": 8, "main_series": "Series A", "group": "Generalist"}, {"id": "Longwood Fund", "investments": 21, "main_series": "Series A", "group": "Other life science"}, {"id": "AbbVie", "investments": 21, "main_series": "Series A", "group": "Pharma"}, {"id": "GV", "investments": 42, "main_series": "Series A", "group": "Tier A life science"}, {"id": "Lumira Ventures", "investments": 13, "main_series": "Series A", "group": "Other life science"}, {"id": "Merck", "investments": 31, "main_series": "Series A", "group": "Pharma"}, {"id": "Alta Partners", "investments": 36, "main_series": "Series A", "group": "Other life science"}, {"id": "Science Ventures", "investments": 27, "main_series": "Series A", "group": "Other life science"}], "links": [{"source": "Eli Lilly", "target": "AbbVie", "value": 5, "source_investments": 21, "target_investments": 21}, {"source": "Eli Lilly", "target": "Alexandria", "value": 12, "source_investments": 21, "target_investments": 102}, {"source": "Eli Lilly", "target": "ARCH Venture Partners", "value": 6, "source_investments": 21, "target_investments": 103}, {"source": "Eli Lilly", "target": "Johnson & Johnson Innovation", "value": 7, "source_investments": 21, "target_investments": 34}, {"source": "Eli Lilly", "target": "Pfizer", "value": 5, "source_investments": 21, "target_investments": 40}, {"source": "Logos Capital", "target": "Cormorant Asset Management", "value": 5, "source_investments": 14, "target_investments": 21}, {"source": "Logos Capital", "target": "Janus Henderson", "value": 5, "source_investments": 14, "target_investments": 14}, {"source": "Logos Capital", "target": "Surveyor Capital", "value": 5, "source_investments": 14, "target_investments": 14}, {"source": "Samsara BioCapital", "target": "EcoR1 Capital", "value": 5, "source_investments": 23, "target_investments": 14}, {"source": "Johnson & Johnson Innovation", "target": "AbbVie", "value": 5, "source_investments": 34, "target_investments": 21}, {"source": "Johnson & Johnson Innovation", "target": "Alexandria", "value": 10, "source_investments": 34, "target_investments": 102}, {"source": "Johnson & Johnson Innovation", "target": "ARCH Venture Partners", "value": 7, "source_investments": 34, "target_investments": 103}, {"source": "Johnson & Johnson Innovation", "target": "Eli Lilly", "value": 5, "source_investments": 34, "target_investments": 21}, {"source": "Johnson & Johnson Innovation", "target": "Pfizer", "value": 6, "source_investments": 34, "target_investments": 40}, {"source": "Johnson & Johnson Innovation", "target": "Vertex Ventures", "value": 5, "source_investments": 34, "target_investments": 11}, {"source": "Roche Venture Fund", "target": "5AM Ventures", "value": 7, "source_investments": 21, "target_investments": 52}, {"source": "Roche Venture Fund", "target": "RiverVest", "value": 6, "source_investments": 21, "target_investments": 17}, {"source": "Matrix Partners", "target": "Matrix Partners China", "value": 7, "source_investments": 9, "target_investments": 7}, {"source": "DCVC", "target": "AME Cloud Ventures", "value": 5, "source_investments": 28, "target_investments": 11}, {"source": "DCVC", "target": "Lux Capital", "value": 5, "source_investments": 28, "target_investments": 29}, {"source": "Flagship Pioneering", "target": "Polaris Ventures", "value": 5, "source_investments": 27, "target_investments": 51}, {"source": "Flagship Pioneering", "target": "ARCH Venture Partners", "value": 5, "source_investments": 27, "target_investments": 103}, {"source": "Venrock", "target": "ARCH Venture Partners", "value": 9, "source_investments": 30, "target_investments": 103}, {"source": "Morgenthaler Ventures", "target": "HealthCare Ventures", "value": 5, "source_investments": 12, "target_investments": 21}, {"source": "Eight Roads Ventures", "target": "F-Prime Capital", "value": 11, "source_investments": 12, "target_investments": 56}, {"source": "Vida Ventures", "target": "Nextech Invest", "value": 5, "source_investments": 17, "target_investments": 12}, {"source": "Vida Ventures", "target": "EcoR1 Capital", "value": 5, "source_investments": 17, "target_investments": 14}, {"source": "Sofinnova", "target": "Alta Partners", "value": 5, "source_investments": 69, "target_investments": 36}, {"source": "Sofinnova", "target": "Atlas Venture", "value": 5, "source_investments": 69, "target_investments": 69}, {"source": "Sofinnova", "target": "Vivo Capital", "value": 5, "source_investments": 69, "target_investments": 35}, {"source": "Sofinnova", "target": "Novo Holding", "value": 6, "source_investments": 69, "target_investments": 38}, {"source": "Sofinnova", "target": "Astellas Venture Management", "value": 5, "source_investments": 69, "target_investments": 19}, {"source": "Sofinnova", "target": "Canaan Partners", "value": 5, "source_investments": 69, "target_investments": 37}, {"source": "Sofinnova", "target": "Alexandria", "value": 6, "source_investments": 69, "target_investments": 102}, {"source": "EcoR1 Capital", "target": "Polaris Ventures", "value": 5, "source_investments": 14, "target_investments": 51}, {"source": "EcoR1 Capital", "target": "Samsara BioCapital", "value": 5, "source_investments": 14, "target_investments": 23}, {"source": "EcoR1 Capital", "target": "Vida Ventures", "value": 5, "source_investments": 14, "target_investments": 17}, {"source": "Takeda", "target": "Alexandria", "value": 5, "source_investments": 29, "target_investments": 102}, {"source": "Partners Innovation Fund", "target": "Atlas Venture", "value": 7, "source_investments": 20, "target_investments": 69}, {"source": "Hatteras Venture Partners", "target": "OUP Osage University Partners", "value": 5, "source_investments": 23, "target_investments": 39}, {"source": "Hatteras Venture Partners", "target": "Alexandria", "value": 5, "source_investments": 23, "target_investments": 102}, {"source": "Nextech Invest", "target": "Vida Ventures", "value": 5, "source_investments": 12, "target_investments": 17}, {"source": "Domain Associates", "target": "Frazier Healthcare Partners", "value": 5, "source_investments": 39, "target_investments": 37}, {"source": "Washington Research Foundation", "target": "ARCH Venture Partners", "value": 5, "source_investments": 9, "target_investments": 103}, {"source": "Catalio Capital Management", "target": "Alexandria", "value": 5, "source_investments": 10, "target_investments": 102}, {"source": "The Column Group", "target": "Lux Capital", "value": 5, "source_investments": 28, "target_investments": 29}, {"source": "Connecticut Innovations", "target": "Elm Street Ventures", "value": 5, "source_investments": 18, "target_investments": 8}, {"source": "Lux Capital", "target": "Alexandria", "value": 6, "source_investments": 29, "target_investments": 102}, {"source": "Lux Capital", "target": "Polaris Ventures", "value": 5, "source_investments": 29, "target_investments": 51}, {"source": "Lux Capital", "target": "The Column Group", "value": 5, "source_investments": 29, "target_investments": 28}, {"source": "Lux Capital", "target": "DCVC", "value": 5, "source_investments": 29, "target_investments": 28}, {"source": "Lux Capital", "target": "Obvious Ventures", "value": 7, "source_investments": 29, "target_investments": 11}, {"source": "Pontifax", "target": "OrbiMed", "value": 5, "source_investments": 11, "target_investments": 91}, {"source": "5AM Ventures", "target": "Versant Ventures", "value": 8, "source_investments": 52, "target_investments": 67}, {"source": "5AM Ventures", "target": "ARCH Venture Partners", "value": 5, "source_investments": 52, "target_investments": 103}, {"source": "5AM Ventures", "target": "Sofinnova", "value": 5, "source_investments": 52, "target_investments": 69}, {"source": "5AM Ventures", "target": "Roche Venture Fund", "value": 7, "source_investments": 52, "target_investments": 21}, {"source": "5AM Ventures", "target": "Canaan Partners", "value": 5, "source_investments": 52, "target_investments": 37}, {"source": "5AM Ventures", "target": "Alexandria", "value": 5, "source_investments": 52, "target_investments": 102}, {"source": "Canaan Partners", "target": "Sofinnova", "value": 5, "source_investments": 37, "target_investments": 69}, {"source": "Canaan Partners", "target": "5AM Ventures", "value": 5, "source_investments": 37, "target_investments": 52}, {"source": "Foresite Capital", "target": "ARCH Venture Partners", "value": 8, "source_investments": 15, "target_investments": 103}, {"source": "Foresite Capital", "target": "Alexandria", "value": 5, "source_investments": 15, "target_investments": 102}, {"source": "Foresite Capital", "target": "GV", "value": 5, "source_investments": 15, "target_investments": 42}, {"source": "AME Cloud Ventures", "target": "DCVC", "value": 5, "source_investments": 11, "target_investments": 28}, {"source": "Altitude Life Science Ventures", "target": "ARCH Venture Partners", "value": 7, "source_investments": 11, "target_investments": 103}, {"source": "Surveyor Capital", "target": "Logos Capital", "value": 5, "source_investments": 14, "target_investments": 14}, {"source": "Janus Henderson", "target": "Logos Capital", "value": 5, "source_investments": 14, "target_investments": 14}, {"source": "ARCH Venture Partners", "target": "Venrock", "value": 9, "source_investments": 103, "target_investments": 30}, {"source": "ARCH Venture Partners", "target": "5AM Ventures", "value": 5, "source_investments": 103, "target_investments": 52}, {"source": "ARCH Venture Partners", "target": "Alexandria", "value": 25, "source_investments": 103, "target_investments": 102}, {"source": "ARCH Venture Partners", "target": "Polaris Ventures", "value": 5, "source_investments": 103, "target_investments": 51}, {"source": "ARCH Venture Partners", "target": "Flagship Pioneering", "value": 5, "source_investments": 103, "target_investments": 27}, {"source": "ARCH Venture Partners", "target": "Washington Research Foundation", "value": 5, "source_investments": 103, "target_investments": 9}, {"source": "ARCH Venture Partners", "target": "Altitude Life Science Ventures", "value": 7, "source_investments": 103, "target_investments": 11}, {"source": "ARCH Venture Partners", "target": "F-Prime Capital", "value": 9, "source_investments": 103, "target_investments": 56}, {"source": "ARCH Venture Partners", "target": "Lilly Asia Ventures", "value": 8, "source_investments": 103, "target_investments": 22}, {"source": "ARCH Venture Partners", "target": "Merck", "value": 5, "source_investments": 103, "target_investments": 31}, {"source": "ARCH Venture Partners", "target": "AbbVie", "value": 5, "source_investments": 103, "target_investments": 21}, {"source": "ARCH Venture Partners", "target": "Eli Lilly", "value": 5, "source_investments": 103, "target_investments": 21}, {"source": "ARCH Venture Partners", "target": "Johnson & Johnson Innovation", "value": 7, "source_investments": 103, "target_investments": 34}, {"source": "ARCH Venture Partners", "target": "GV", "value": 16, "source_investments": 103, "target_investments": 42}, {"source": "ARCH Venture Partners", "target": "Foresite Capital", "value": 8, "source_investments": 103, "target_investments": 15}, {"source": "Bayer", "target": "Alexandria", "value": 7, "source_investments": 18, "target_investments": 102}, {"source": "Bayer", "target": "Leaps by Bayer", "value": 14, "source_investments": 18, "target_investments": 14}, {"source": "Cormorant Asset Management", "target": "Logos Capital", "value": 5, "source_investments": 21, "target_investments": 14}, {"source": "Astellas Venture Management", "target": "Sofinnova", "value": 5, "source_investments": 19, "target_investments": 69}, {"source": "Astellas Venture Management", "target": "Novartis", "value": 5, "source_investments": 19, "target_investments": 66}, {"source": "Astellas Venture Management", "target": "MPM Capital", "value": 7, "source_investments": 19, "target_investments": 58}, {"source": "Atlas Venture", "target": "Sofinnova", "value": 5, "source_investments": 69, "target_investments": 69}, {"source": "Atlas Venture", "target": "F-Prime Capital", "value": 5, "source_investments": 69, "target_investments": 56}, {"source": "Atlas Venture", "target": "Partners Innovation Fund", "value": 7, "source_investments": 69, "target_investments": 20}, {"source": "Atlas Venture", "target": "New Enterprise Associates", "value": 5, "source_investments": 69, "target_investments": 65}, {"source": "Atlas Venture", "target": "Alexandria", "value": 6, "source_investments": 69, "target_investments": 102}, {"source": "F-Prime Capital", "target": "Eight Roads Ventures", "value": 11, "source_investments": 56, "target_investments": 12}, {"source": "F-Prime Capital", "target": "Atlas Venture", "value": 5, "source_investments": 56, "target_investments": 69}, {"source": "F-Prime Capital", "target": "New Enterprise Associates", "value": 7, "source_investments": 56, "target_investments": 65}, {"source": "F-Prime Capital", "target": "ARCH Venture Partners", "value": 9, "source_investments": 56, "target_investments": 103}, {"source": "F-Prime Capital", "target": "OrbiMed", "value": 5, "source_investments": 56, "target_investments": 91}, {"source": "F-Prime Capital", "target": "GV", "value": 7, "source_investments": 56, "target_investments": 42}, {"source": "HealthCare Ventures", "target": "Morgenthaler Ventures", "value": 5, "source_investments": 21, "target_investments": 12}, {"source": "Novartis", "target": "New Enterprise Associates", "value": 8, "source_investments": 66, "target_investments": 65}, {"source": "Novartis", "target": "5AM Ventures", "value": 5, "source_investments": 66, "target_investments": 52}, {"source": "Novartis", "target": "Alexandria", "value": 7, "source_investments": 66, "target_investments": 102}, {"source": "Novartis", "target": "OrbiMed", "value": 6, "source_investments": 66, "target_investments": 91}, {"source": "Novartis", "target": "Astellas Venture Management", "value": 6, "source_investments": 66, "target_investments": 19}, {"source": "Novartis", "target": "OUP Osage University Partners", "value": 5, "source_investments": 66, "target_investments": 39}, {"source": "Novartis", "target": "Atlas Venture", "value": 5, "source_investments": 66, "target_investments": 69}, {"source": "Novartis", "target": "MPM Capital", "value": 7, "source_investments": 66, "target_investments": 58}, {"source": "Novartis", "target": "Johnson & Johnson Innovation", "value": 5, "source_investments": 66, "target_investments": 34}, {"source": "Polaris Ventures", "target": "Flagship Pioneering", "value": 5, "source_investments": 51, "target_investments": 27}, {"source": "Polaris Ventures", "target": "Lux Capital", "value": 5, "source_investments": 51, "target_investments": 29}, {"source": "Polaris Ventures", "target": "ARCH Venture Partners", "value": 5, "source_investments": 51, "target_investments": 103}, {"source": "Polaris Ventures", "target": "Alexandria", "value": 6, "source_investments": 51, "target_investments": 102}, {"source": "Polaris Ventures", "target": "EcoR1 Capital", "value": 5, "source_investments": 51, "target_investments": 14}, {"source": "Polaris Ventures", "target": "GV", "value": 5, "source_investments": 51, "target_investments": 42}, {"source": "Novo Holding", "target": "Sofinnova", "value": 6, "source_investments": 38, "target_investments": 69}, {"source": "New Enterprise Associates", "target": "Versant Ventures", "value": 8, "source_investments": 65, "target_investments": 67}, {"source": "New Enterprise Associates", "target": "Novartis", "value": 7, "source_investments": 65, "target_investments": 66}, {"source": "New Enterprise Associates", "target": "OrbiMed", "value": 6, "source_investments": 65, "target_investments": 91}, {"source": "New Enterprise Associates", "target": "F-Prime Capital", "value": 7, "source_investments": 65, "target_investments": 56}, {"source": "New Enterprise Associates", "target": "Pfizer", "value": 5, "source_investments": 65, "target_investments": 40}, {"source": "New Enterprise Associates", "target": "Atlas Venture", "value": 5, "source_investments": 65, "target_investments": 69}, {"source": "New Enterprise Associates", "target": "Alexandria", "value": 7, "source_investments": 65, "target_investments": 102}, {"source": "New Enterprise Associates", "target": "Lundbeck", "value": 5, "source_investments": 65, "target_investments": 9}, {"source": "RiverVest", "target": "Roche Venture Fund", "value": 6, "source_investments": 17, "target_investments": 21}, {"source": "Lilly Asia Ventures", "target": "ARCH Venture Partners", "value": 8, "source_investments": 22, "target_investments": 103}, {"source": "Lilly Asia Ventures", "target": "Vivo Capital", "value": 6, "source_investments": 22, "target_investments": 35}, {"source": "Alexandria", "target": "ARCH Venture Partners", "value": 25, "source_investments": 102, "target_investments": 103}, {"source": "Alexandria", "target": "Lux Capital", "value": 6, "source_investments": 102, "target_investments": 29}, {"source": "Alexandria", "target": "Novartis", "value": 6, "source_investments": 102, "target_investments": 66}, {"source": "Alexandria", "target": "Polaris Ventures", "value": 6, "source_investments": 102, "target_investments": 51}, {"source": "Alexandria", "target": "Amgen", "value": 5, "source_investments": 102, "target_investments": 22}, {"source": "Alexandria", "target": "Lundbeck", "value": 5, "source_investments": 102, "target_investments": 9}, {"source": "Alexandria", "target": "New Enterprise Associates", "value": 7, "source_investments": 102, "target_investments": 65}, {"source": "Alexandria", "target": "Pfizer", "value": 14, "source_investments": 102, "target_investments": 40}, {"source": "Alexandria", "target": "Sofinnova", "value": 6, "source_investments": 102, "target_investments": 69}, {"source": "Alexandria", "target": "AbbVie", "value": 12, "source_investments": 102, "target_investments": 21}, {"source": "Alexandria", "target": "Eli Lilly", "value": 8, "source_investments": 102, "target_investments": 21}, {"source": "Alexandria", "target": "Johnson & Johnson Innovation", "value": 10, "source_investments": 102, "target_investments": 34}, {"source": "Alexandria", "target": "5AM Ventures", "value": 5, "source_investments": 102, "target_investments": 52}, {"source": "Alexandria", "target": "Alta Partners", "value": 5, "source_investments": 102, "target_investments": 36}, {"source": "Alexandria", "target": "Foresite Capital", "value": 5, "source_investments": 102, "target_investments": 15}, {"source": "Alexandria", "target": "GV", "value": 6, "source_investments": 102, "target_investments": 42}, {"source": "Alexandria", "target": "Atlas Venture", "value": 6, "source_investments": 102, "target_investments": 69}, {"source": "Alexandria", "target": "Takeda", "value": 5, "source_investments": 102, "target_investments": 29}, {"source": "Alexandria", "target": "Vertex Ventures", "value": 5, "source_investments": 102, "target_investments": 11}, {"source": "Alexandria", "target": "Third Rock Ventures", "value": 7, "source_investments": 102, "target_investments": 42}, {"source": "Alexandria", "target": "Casdin Capital", "value": 8, "source_investments": 102, "target_investments": 33}, {"source": "Alexandria", "target": "Hatteras Venture Partners", "value": 5, "source_investments": 102, "target_investments": 23}, {"source": "Alexandria", "target": "Leaps by Bayer", "value": 6, "source_investments": 102, "target_investments": 14}, {"source": "Alexandria", "target": "Catalio Capital Management", "value": 5, "source_investments": 102, "target_investments": 10}, {"source": "Amgen", "target": "Alexandria", "value": 5, "source_investments": 22, "target_investments": 102}, {"source": "Fonds de solidarit FTQ", "target": "Lumira Ventures", "value": 5, "source_investments": 7, "target_investments": 13}, {"source": "OrbiMed", "target": "MPM Capital", "value": 5, "source_investments": 91, "target_investments": 58}, {"source": "OrbiMed", "target": "Versant Ventures", "value": 7, "source_investments": 91, "target_investments": 67}, {"source": "OrbiMed", "target": "Frazier Healthcare Partners", "value": 5, "source_investments": 91, "target_investments": 37}, {"source": "OrbiMed", "target": "New Enterprise Associates", "value": 6, "source_investments": 91, "target_investments": 65}, {"source": "OrbiMed", "target": "Novartis", "value": 6, "source_investments": 91, "target_investments": 66}, {"source": "OrbiMed", "target": "OUP Osage University Partners", "value": 5, "source_investments": 91, "target_investments": 39}, {"source": "OrbiMed", "target": "F-Prime Capital", "value": 5, "source_investments": 91, "target_investments": 56}, {"source": "OrbiMed", "target": "Pontifax", "value": 5, "source_investments": 91, "target_investments": 11}, {"source": "Third Rock Ventures", "target": "GV", "value": 5, "source_investments": 42, "target_investments": 42}, {"source": "Third Rock Ventures", "target": "Alexandria", "value": 7, "source_investments": 42, "target_investments": 102}, {"source": "Third Rock Ventures", "target": "Casdin Capital", "value": 6, "source_investments": 42, "target_investments": 33}, {"source": "Third Rock Ventures", "target": "Invus", "value": 5, "source_investments": 42, "target_investments": 13}, {"source": "Vivo Capital", "target": "Sofinnova", "value": 5, "source_investments": 35, "target_investments": 69}, {"source": "Vivo Capital", "target": "Lilly Asia Ventures", "value": 6, "source_investments": 35, "target_investments": 22}, {"source": "OUP Osage University Partners", "target": "OrbiMed", "value": 5, "source_investments": 39, "target_investments": 91}, {"source": "OUP Osage University Partners", "target": "Hatteras Venture Partners", "value": 5, "source_investments": 39, "target_investments": 23}, {"source": "Frazier Healthcare Partners", "target": "Domain Associates", "value": 5, "source_investments": 37, "target_investments": 39}, {"source": "Frazier Healthcare Partners", "target": "OrbiMed", "value": 5, "source_investments": 37, "target_investments": 91}, {"source": "Pfizer", "target": "New Enterprise Associates", "value": 5, "source_investments": 40, "target_investments": 65}, {"source": "Pfizer", "target": "Alexandria", "value": 14, "source_investments": 40, "target_investments": 102}, {"source": "Pfizer", "target": "AbbVie", "value": 6, "source_investments": 40, "target_investments": 21}, {"source": "Pfizer", "target": "Johnson & Johnson Innovation", "value": 6, "source_investments": 40, "target_investments": 34}, {"source": "Leaps by Bayer", "target": "Alexandria", "value": 6, "source_investments": 14, "target_investments": 102}, {"source": "Invus", "target": "Third Rock Ventures", "value": 5, "source_investments": 13, "target_investments": 42}, {"source": "Lundbeck", "target": "Alexandria", "value": 5, "source_investments": 9, "target_investments": 102}, {"source": "Lundbeck", "target": "New Enterprise Associates", "value": 5, "source_investments": 9, "target_investments": 65}, {"source": "MPM Capital", "target": "OrbiMed", "value": 5, "source_investments": 58, "target_investments": 91}, {"source": "MPM Capital", "target": "Longwood Fund", "value": 7, "source_investments": 58, "target_investments": 21}, {"source": "MPM Capital", "target": "Astellas Venture Management", "value": 7, "source_investments": 58, "target_investments": 19}, {"source": "MPM Capital", "target": "Novartis", "value": 6, "source_investments": 58, "target_investments": 66}, {"source": "Obvious Ventures", "target": "Lux Capital", "value": 7, "source_investments": 11, "target_investments": 29}, {"source": "Casdin Capital", "target": "Alexandria", "value": 8, "source_investments": 33, "target_investments": 102}, {"source": "Casdin Capital", "target": "GV", "value": 7, "source_investments": 33, "target_investments": 42}, {"source": "Casdin Capital", "target": "Third Rock Ventures", "value": 6, "source_investments": 33, "target_investments": 42}, {"source": "Versant Ventures", "target": "OrbiMed", "value": 7, "source_investments": 67, "target_investments": 91}, {"source": "Versant Ventures", "target": "New Enterprise Associates", "value": 8, "source_investments": 67, "target_investments": 65}, {"source": "Versant Ventures", "target": "5AM Ventures", "value": 8, "source_investments": 67, "target_investments": 52}, {"source": "Elm Street Ventures", "target": "Connecticut Innovations", "value": 5, "source_investments": 8, "target_investments": 18}, {"source": "Longwood Fund", "target": "MPM Capital", "value": 7, "source_investments": 21, "target_investments": 58}, {"source": "AbbVie", "target": "Alexandria", "value": 12, "source_investments": 21, "target_investments": 102}, {"source": "AbbVie", "target": "ARCH Venture Partners", "value": 5, "source_investments": 21, "target_investments": 103}, {"source": "AbbVie", "target": "Eli Lilly", "value": 5, "source_investments": 21, "target_investments": 21}, {"source": "AbbVie", "target": "Johnson & Johnson Innovation", "value": 5, "source_investments": 21, "target_investments": 34}, {"source": "AbbVie", "target": "Pfizer", "value": 5, "source_investments": 21, "target_investments": 40}, {"source": "GV", "target": "Third Rock Ventures", "value": 5, "source_investments": 42, "target_investments": 42}, {"source": "GV", "target": "ARCH Venture Partners", "value": 16, "source_investments": 42, "target_investments": 103}, {"source": "GV", "target": "Polaris Ventures", "value": 5, "source_investments": 42, "target_investments": 51}, {"source": "GV", "target": "Alexandria", "value": 6, "source_investments": 42, "target_investments": 102}, {"source": "GV", "target": "Foresite Capital", "value": 5, "source_investments": 42, "target_investments": 15}, {"source": "GV", "target": "Casdin Capital", "value": 7, "source_investments": 42, "target_investments": 33}, {"source": "GV", "target": "F-Prime Capital", "value": 7, "source_investments": 42, "target_investments": 56}, {"source": "Lumira Ventures", "target": "Fonds de solidarit FTQ", "value": 5, "source_investments": 13, "target_investments": 7}, {"source": "Merck", "target": "ARCH Venture Partners", "value": 5, "source_investments": 31, "target_investments": 103}, {"source": "Alta Partners", "target": "Sofinnova", "value": 5, "source_investments": 36, "target_investments": 69}, {"source": "Alta Partners", "target": "Alexandria", "value": 5, "source_investments": 36, "target_investments": 102}, {"source": "Science Ventures", "target": "New Science Ventures", "value": 7, "source_investments": 27, "target_investments": 7}, {"source": "Science Ventures", "target": "Altitude Life Science Ventures", "value": 11, "source_investments": 27, "target_investments": 11}, {"source": "Science Ventures", "target": "ARCH Venture Partners", "value": 7, "source_investments": 27, "target_investments": 103}]}